Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: AMPA antagonists - Egis Pharmaceuticals

X
Drug Profile

Research programme: AMPA antagonists - Egis Pharmaceuticals

Alternative Names: EGIS-10608; EGIS-10609; EGIS-10733; EGIS-11229

Latest Information Update: 14 Sep 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egis Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy; Neurological disorders; Stroke

Most Recent Events

  • 17 Oct 2007 Pharmacodynamics data from preclinical trials in Neurological disorders presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
  • 21 Sep 2005 Preclinical trials in Stroke in Hungary (unspecified route)
  • 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Neurological disorders pharmacodynamics section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top